ELOA

Summary

ELOA (elongin A, HGNC:11620) is a protein-coding gene on chromosome 1p36.11, encoding Elongin-A (Q14241). SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. It is a selective cancer dependency (DepMap: 10.6% of cell lines).

This gene encodes the protein elongin A, which is a subunit of the transcription factor B (SIII) complex. The SIII complex is composed of elongins A/A2, B and C. It activates elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin A functions as the transcriptionally active component of the SIII complex, whereas elongins B and C are regulatory subunits. Elongin A2 is specifically expressed in the testis, and capable of forming a stable complex with elongins B and C. The von Hippel-Lindau tumor suppressor protein binds to elongins B and C, and thereby inhibits transcription elongation.

Source: NCBI Gene 6924 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 119 total
• Cancer dependency (DepMap): dependent in 10.6% of screened cell lines
• MANE Select transcript: NM_003198

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11620
Approved symbol	ELOA
Name	elongin A
Location	1p36.11
Locus type	gene with protein product
Status	Approved
Aliases	SIII, TCEB3A, ELOA1
Ensembl gene	ENSG00000011007
Ensembl biotype	protein_coding
OMIM	600786
Entrez	6924

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000418390, ENST00000487554, ENST00000609199, ENST00000613537, ENST00000907871

RefSeq mRNA: 1 — MANE Select: NM_003198 NM_003198

CCDS: CCDS239

Canonical transcript exons

ENST00000613537 — 11 exons

Exon	Start	End
ENSE00000388637	23754100	23754255
ENSE00000388638	23754363	23754460
ENSE00000388639	23755843	23756023
ENSE00000560760	23750845	23752030
ENSE00000758349	23756953	23757125
ENSE00000758350	23756274	23756385
ENSE00000758354	23752407	23752518
ENSE00001596651	23759512	23762059
ENSE00003559637	23749021	23749077
ENSE00003565857	23749842	23749948
ENSE00003703844	23743471	23743578

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 95.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.9516 / max 243.7578, expressed in 1822 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1363	27.8081	1821
1362	1.7905	1284
1361	0.3530	101

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	95.23	gold quality
lower lobe of lung	UBERON:0008949	94.72	gold quality
cardia of stomach	UBERON:0001162	94.67	gold quality
gluteal muscle	UBERON:0002000	94.06	gold quality
cervix squamous epithelium	UBERON:0006922	93.49	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.21	gold quality
left ventricle myocardium	UBERON:0006566	93.20	gold quality
upper arm skin	UBERON:0004263	93.14	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.00	gold quality
cervix epithelium	UBERON:0004801	92.80	gold quality
gingival epithelium	UBERON:0001949	92.61	gold quality
biceps brachii	UBERON:0001507	92.56	gold quality
diaphragm	UBERON:0001103	92.43	gold quality
tongue squamous epithelium	UBERON:0006919	92.29	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.20	gold quality
islet of Langerhans	UBERON:0000006	92.10	gold quality
superficial temporal artery	UBERON:0001614	92.06	gold quality
mucosa of urinary bladder	UBERON:0001259	92.01	gold quality
skeletal muscle tissue	UBERON:0001134	91.96	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.96	gold quality
pylorus	UBERON:0001166	91.87	gold quality
muscle tissue	UBERON:0002385	91.74	gold quality
tibialis anterior	UBERON:0001385	91.68	gold quality
oviduct epithelium	UBERON:0004804	91.66	gold quality
deltoid	UBERON:0001476	91.65	gold quality
type B pancreatic cell	CL:0000169	91.46	silver quality
triceps brachii	UBERON:0001509	91.46	gold quality
myocardium	UBERON:0002349	91.22	gold quality
gingiva	UBERON:0001828	91.05	gold quality
nasal cavity epithelium	UBERON:0005384	90.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

123 targeting ELOA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-95-5P	99.89	72.17	3973

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• Elongin A transcription elongation activity, but not its ubiquitination activity, is most important for its function in induction of transcription of ATF3 and p21. (PMID:23828199)
• TCEB3C is a putative tumor suppressor gene of small intestinal neuroendocrine tumors (PMID:24351681)
• the Elongin A ubiquitin ligase and the CSB protein function together in a common pathway in response to Pol II stalling and DNA damage (PMID:28292928)
• Elongin A regulates transcription in vivo through enhanced RNA polymerase processivity. (PMID:33298525)
• TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1. (PMID:38661028)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	eloa	ENSDARG00000102365
mus_musculus	Eloa	ENSMUSG00000028668
rattus_norvegicus	Eloa	ENSRNOG00000010902
drosophila_melanogaster	EloA	FBGN0039066
caenorhabditis_elegans		WBGENE00010990

Paralogs (1): ELOA2 (ENSG00000206181)

Protein

Protein identifiers

Elongin-A — Q14241 (reviewed: Q14241)

Alternative names: Elongin 110 kDa subunit, RNA polymerase II transcription factor SIII subunit A1, SIII p110, Transcription elongation factor B polypeptide 3

All UniProt accessions (2): Q14241, A0AAA9X7E5

UniProt curated annotations — full annotation on UniProt →

Function. SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex). As part of a multisubunit complex composed of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5; polyubiquitinates monoubiquitinated POLR2A.

Subunit / interactions. Heterotrimer of an A (ELOA, ELOA2 or ELOA3P), ELOB and ELOC subunit. Part of a multisubunit ubiquitin ligase complex consisting of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5. Interacts with ERCC6; the interaction is induced by DNA damaging agents or inhibitors of RNA polymerase II elongation. Interacts (via BC-box) with CUL5.

Subcellular location. Nucleus.

Domain organisation. The BC-box, which mediates binding to the elongin BC complex, has the consensus sequence [APST]-L-x(3)-C-x(3)-[AILV].

Miscellaneous. Produced by alternative initiation. Based on proteomic data.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14241-2	2	yes
Q14241-1	1

RefSeq proteins (1): NP_003189* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001810	F-box_dom	Domain
IPR003617	TFIIS/CRSP70_N_sub	Domain
IPR010684	RNA_pol_II_trans_fac_SIII_A	Family
IPR017923	TFIIS_N	Domain
IPR035441	TFIIS/LEDGF_dom_sf	Homologous_superfamily
IPR051870	Elongin-A_domain	Family

Pfam: PF06881, PF08711

UniProt features (43 total): helix 12, compositionally biased region 9, modified residue 6, region of interest 5, sequence variant 3, turn 3, domain 2, chain 1, splice variant 1, strand 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
4HFX	X-RAY DIFFRACTION	2.54
8OEW	ELECTRON MICROSCOPY	2.8
8OEV	ELECTRON MICROSCOPY	2.86
8OF0	ELECTRON MICROSCOPY	3.05
6ZUZ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14241-F1	57.63	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 196, 384, 387, 394, 434, 516

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-112382	Formation of RNA Pol II elongation complex
R-HSA-167152	Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200	Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-167238	Pausing and recovery of Tat-mediated HIV elongation
R-HSA-167243	Tat-mediated HIV elongation arrest and recovery
R-HSA-167246	Tat-mediated elongation of the HIV-1 transcript
R-HSA-167287	HIV elongation arrest and recovery
R-HSA-167290	Pausing and recovery of HIV elongation
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes
R-HSA-75955	RNA Polymerase II Transcription Elongation

MSigDB gene sets: 167 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, MODULE_229, WEI_MYCN_TARGETS_WITH_E_BOX, REACTOME_HIV_INFECTION, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS, WTGAAAT_UNKNOWN, TCF11_01, MODULE_123, DEN_INTERACT_WITH_LCA5, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GARY_CD5_TARGETS_DN, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, CART1_01

GO Biological Process (5): regulation of transcription by RNA polymerase II (GO:0006357), transcription initiation at RNA polymerase II promoter (GO:0006367), transcription elongation by RNA polymerase II (GO:0006368), regulation of DNA-templated transcription (GO:0006355), transcription by RNA polymerase II (GO:0006366)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), nucleoplasm (GO:0005654), elongin complex (GO:0070449), site of DNA damage (GO:0090734), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Transcription of the HIV genome	5
RNA Polymerase II Transcription	2
RNA Polymerase II Transcription Elongation	1
Tat-mediated elongation of the HIV-1 transcript	1
HIV Transcription Elongation	1
Transcriptional Regulation by TP53	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	3
DNA-templated transcription	2
cellular anatomical structure	2
regulation of DNA-templated transcription	1
DNA-templated transcription initiation	1
DNA-templated transcription elongation	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
binding	1
nuclear lumen	1
transcription elongation factor complex	1
chromosome	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1403 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELOA	ELOC	Q15369	987
ELOA	ELOB	Q15370	958
ELOA	REXO1	Q8N1G1	918
ELOA	CUL5	Q93034	767
ELOA	VHL	P40337	708
ELOA	TCEA2	Q15560	702
ELOA	TCEA3	O75764	694
ELOA	CUL2	Q13617	631
ELOA	MED26	O95402	618
ELOA	POLR2A	P24928	613
ELOA	LRRC41	Q15345	592
ELOA	TCEA1	P23193	579
ELOA	PPIE	Q9UNP9	519
ELOA	RNF7	Q9UBF6	504
ELOA	CCNT1	O60563	498

IntAct

227 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
PLK4	ELOA	psi-mi:“MI:0915”(physical association)	0.720
ELOA	MDFI	psi-mi:“MI:0915”(physical association)	0.720
MDFI	ELOA	psi-mi:“MI:0915”(physical association)	0.720
ELOA	FLJ13057	psi-mi:“MI:0915”(physical association)	0.560
ELOA	KRT40	psi-mi:“MI:0915”(physical association)	0.560
HOMEZ	ELOA	psi-mi:“MI:0915”(physical association)	0.560
ELOA	CEP57L1	psi-mi:“MI:0915”(physical association)	0.560
ELOA	FAM9B	psi-mi:“MI:0915”(physical association)	0.560
CBY2	ELOA	psi-mi:“MI:0915”(physical association)	0.560
ELOA	CEP70	psi-mi:“MI:0915”(physical association)	0.560
JAKMIP2	ELOA	psi-mi:“MI:0915”(physical association)	0.560
ELOA	TRIM54	psi-mi:“MI:0915”(physical association)	0.560
MID2	ELOA	psi-mi:“MI:0915”(physical association)	0.560
ELOA		psi-mi:“MI:0915”(physical association)	0.560
ELOA	HOMEZ	psi-mi:“MI:0915”(physical association)	0.560
ELOA	CBY2	psi-mi:“MI:0915”(physical association)	0.560
ELOA	JAKMIP2	psi-mi:“MI:0915”(physical association)	0.560
TRIM54	ELOA	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (323): TCEB3 (Co-localization), PSMB9 (Co-localization), POLR2A (Co-localization), POLR2B (Co-localization), POLR2C (Co-localization), POLR2D (Co-localization), POLR2E (Co-localization), POLR2F (Co-localization), POLR2G (Co-localization), POLR2H (Co-localization), POLR2I (Co-localization), POLR2L (Co-localization), POLR2J (Co-localization), POLR2K (Co-localization), TCEB3 (Co-localization)

ESM2 similar proteins: A0JNI5, A2AJT4, D3ZTQ1, O35691, O75376, P79149, Q05519, Q12872, Q14241, Q149C2, Q3USH5, Q4KKX4, Q4R6F6, Q53F19, Q568R1, Q569Z6, Q5BJ39, Q5BL56, Q5HZB6, Q5M7V8, Q5R5X0, Q5SFM8, Q5T8P6, Q5ZM19, Q60974, Q63187, Q6DFQ2, Q6NZN0, Q6PJT7, Q6WKW9, Q6ZPZ3, Q8BZR9, Q8BZX4, Q8CB77, Q8CFC7, Q8K019, Q8K3W3, Q8K3X0, Q8N2M8, Q8QG78

Diamond homologs: A5PKE4, B0UYI1, F4J4Y5, O75764, P23881, Q14241, Q2KI09, Q5XIC7, Q63187, Q8CB77, Q8R2M0, Q96MN5, Q9FHK9, A5PK23, O95402, P07273, P0C8F5, P0C8F6, P0C8F7, P0C8F8, P10711, P20232, P23193, P27948, P49373, P52652, Q04307, Q07271, Q148K0, Q15560, Q29RL9, Q2M2S7, Q3US16, Q4KLL0, Q54YG9, Q56254, Q5UQS8, Q63799, Q6GZP4, Q7TN02

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 112 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of RNA Pol II elongation complex	5	15.9×	2e-03
RNA Polymerase II Transcription Elongation	5	15.9×	2e-03
RNA Polymerase II Pre-transcription Events	6	13.5×	2e-03
CHD1 and CHD2 subfamily	6	10.7×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

119 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	104
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1196 predictions. Top by Δscore:

Variant	Effect	Δscore
1:23743574:AGAAG:A	donor_gain	1.0000
1:23743575:GAAG:G	donor_gain	1.0000
1:23743575:GAAGG:G	donor_gain	1.0000
1:23743576:AAG:A	donor_gain	1.0000
1:23743577:AG:A	donor_gain	1.0000
1:23743577:AGG:A	donor_loss	1.0000
1:23743578:GG:G	donor_gain	1.0000
1:23743579:G:GA	donor_loss	1.0000
1:23743579:G:GG	donor_gain	1.0000
1:23749017:GCA:G	acceptor_loss	1.0000
1:23749019:A:AG	acceptor_gain	1.0000
1:23749020:G:GA	acceptor_gain	1.0000
1:23749020:GC:G	acceptor_gain	1.0000
1:23749020:GCT:G	acceptor_gain	1.0000
1:23749020:GCTA:G	acceptor_gain	1.0000
1:23749020:GCTAT:G	acceptor_gain	1.0000
1:23749075:GCG:G	donor_gain	1.0000
1:23749078:G:GG	donor_gain	1.0000
1:23749079:T:A	donor_loss	1.0000
1:23749836:TTTTA:T	acceptor_loss	1.0000
1:23749837:TTTA:T	acceptor_loss	1.0000
1:23749838:TTAG:T	acceptor_loss	1.0000
1:23749839:TAG:T	acceptor_loss	1.0000
1:23749841:GGA:G	acceptor_gain	1.0000
1:23749841:GGAGA:G	acceptor_gain	1.0000
1:23749944:GAACG:G	donor_gain	1.0000
1:23749949:G:GA	donor_loss	1.0000
1:23749949:G:GG	donor_gain	1.0000
1:23750838:A:AG	acceptor_gain	1.0000
1:23750839:T:G	acceptor_gain	1.0000

AlphaMissense

5241 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:23743541:T:C	L39P	1.000
1:23749043:T:C	L59P	1.000
1:23749073:T:A	L69H	1.000
1:23749855:G:A	G75E	1.000
1:23749864:T:A	V78E	1.000
1:23749903:C:A	A91D	1.000
1:23749923:T:A	W98R	1.000
1:23749923:T:C	W98R	1.000
1:23749924:G:C	W98S	1.000
1:23749925:G:C	W98C	1.000
1:23749925:G:T	W98C	1.000
1:23754178:G:A	G565D	1.000
1:23754227:C:G	C581W	1.000
1:23754435:T:C	L615P	1.000
1:23755870:T:A	W633R	1.000
1:23755870:T:C	W633R	1.000
1:23755872:G:C	W633C	1.000
1:23755872:G:T	W633C	1.000
1:23759518:C:A	A781D	1.000
1:23759521:C:A	P782Q	1.000
1:23759527:T:C	M784T	1.000
1:23759534:G:C	K786N	1.000
1:23759534:G:T	K786N	1.000
1:23759552:G:C	K792N	1.000
1:23759552:G:T	K792N	1.000
1:23743553:T:C	L43P	0.999
1:23749034:T:C	L56S	0.999
1:23749043:T:A	L59H	0.999
1:23749073:T:C	L69P	0.999
1:23749852:T:A	V74D	0.999

dbSNP variants (sampled 300 via entrez): RS1000100294 (1:23758196 T>C), RS1000147560 (1:23745511 GA>G), RS1000211 (1:23760694 C>T), RS1000212 (1:23760668 G>A), RS1000213 (1:23760530 T>G), RS1000278163 (1:23743570 C>T), RS1000280673 (1:23752078 CT>C), RS1000288484 (1:23756684 C>T), RS1000309142 (1:23743790 T>C), RS1000484045 (1:23746880 C>G), RS1000533498 (1:23762360 A>G), RS1000578846 (1:23750264 C>T), RS1001007957 (1:23744942 T>G), RS1001150805 (1:23744111 A>C,G), RS1001693994 (1:23750588 T>A)

Disease associations

OMIM: gene MIM:600786 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002740_56	Inflammatory skin disease	1.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	4
Doxorubicin	affects expression, increases expression	2
Nickel	increases expression	2
Tobacco Smoke Pollution	increases expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
coumarin	increases phosphorylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
PCI 5002	affects cotreatment, increases expression	1
Fulvestrant	increases methylation	1
Vorinostat	affects expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Catechin	affects cotreatment, decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Fluorouracil	affects expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	decreases expression	1
Potassium Dichromate	increases expression	1
Ribonucleotides	affects binding	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7B3	SEES3-1V human TCEB3, clone1	Embryonic stem cell	Male
CVCL_A7B4	SEES3-1V human TCEB3, clone2	Embryonic stem cell	Male
CVCL_A7B5	SEES3-1V human TCEB3, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.